Immunomic Therapeutics
Steve Sang Yong Park most recently served as Senior Managing Director and Chairman of Korea Equity Capital Solutions for Macquarie Group located in Seoul, Korea, a position he held until June 2021. In such role, he was responsible for equity capital markets activities for Macquarie Group in Korea. Prior to holding this position, he worked for Macquarie Group in various leadership positions, including Country Head of Macquarie Group Korea, Head of Macquarie Capital and Head of Securities Responsibilities since October 2014. Prior to October 2014, since April 1996, Mr. Park held various leadership positions with other investment banks in Korea, including Goldman Sachs (Asia) LLC, Credit Suisse Securities LTD, NatWest Markets, Morgan Stanley & Co. International Limited and Bankers Trust. He currently serves on the Board of Directors of GS Global and on the Board of Trustees of East Asia Institute. He received a B.A. in Political Economy of Industrial Societies from the University of California in 1990 and a Masters in International Affairs and Certificate of Asian Studies from Columbia University in 1992.
This person is not in the org chart
This person is not in any offices
Immunomic Therapeutics
1 followers
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.